FI119970B - Enrofloksasiini-injektio- tai infuusioliuoksia - Google Patents

Enrofloksasiini-injektio- tai infuusioliuoksia Download PDF

Info

Publication number
FI119970B
FI119970B FI972966A FI972966A FI119970B FI 119970 B FI119970 B FI 119970B FI 972966 A FI972966 A FI 972966A FI 972966 A FI972966 A FI 972966A FI 119970 B FI119970 B FI 119970B
Authority
FI
Finland
Prior art keywords
acid
enrofloxacin
injection
solution
weight
Prior art date
Application number
FI972966A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972966A (fi
FI972966A0 (fi
Inventor
Martin Scheer
Arundev Haribhai Naik
Hanns Peter Mueller
Michael Stegemann
Gerhard Bonse
Martin Hamm
Oliver Vetter
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of FI972966A publication Critical patent/FI972966A/fi
Publication of FI972966A0 publication Critical patent/FI972966A0/fi
Application granted granted Critical
Publication of FI119970B publication Critical patent/FI119970B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI972966A 1995-01-13 1997-07-11 Enrofloksasiini-injektio- tai infuusioliuoksia FI119970B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19500784 1995-01-13
DE19500784A DE19500784A1 (de) 1995-01-13 1995-01-13 Enrofloxacin-Injektions- oder Infusionslösungen
EP9505147 1995-12-28
PCT/EP1995/005147 WO1996021453A1 (de) 1995-01-13 1995-12-28 Enrofloxacin-injektions- oder infusionslösungen

Publications (3)

Publication Number Publication Date
FI972966A FI972966A (fi) 1997-07-11
FI972966A0 FI972966A0 (fi) 1997-07-11
FI119970B true FI119970B (fi) 2009-05-29

Family

ID=7751383

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972966A FI119970B (fi) 1995-01-13 1997-07-11 Enrofloksasiini-injektio- tai infuusioliuoksia

Country Status (28)

Country Link
US (1) US5998418A (xx)
EP (1) EP0806955B1 (xx)
JP (1) JP3835815B2 (xx)
CN (1) CN1125635C (xx)
AR (1) AR002265A1 (xx)
AT (1) ATE261731T1 (xx)
AU (1) AU695171B2 (xx)
BR (1) BR9510444A (xx)
CA (1) CA2210076C (xx)
CZ (1) CZ293934B6 (xx)
DE (2) DE19500784A1 (xx)
DK (1) DK0806955T3 (xx)
ES (1) ES2215183T3 (xx)
FI (1) FI119970B (xx)
HU (1) HU226826B1 (xx)
IL (1) IL116726A (xx)
JO (1) JO1883B1 (xx)
MX (1) MX9705266A (xx)
NO (1) NO313537B1 (xx)
NZ (1) NZ298778A (xx)
PL (1) PL182095B1 (xx)
PT (1) PT806955E (xx)
RU (1) RU2147225C1 (xx)
SK (1) SK284348B6 (xx)
TW (1) TW416852B (xx)
UA (1) UA42819C2 (xx)
WO (1) WO1996021453A1 (xx)
ZA (1) ZA96244B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
JP5002462B2 (ja) * 2004-12-09 2012-08-15 バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 酸によるグルココルチコイドエステルの安定化
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
CN100341510C (zh) * 2005-06-10 2007-10-10 冯莉萍 一种恩诺沙星微囊及制备方法
FR2896416B1 (fr) * 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
US7973022B2 (en) * 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
CN101230333B (zh) * 2007-01-26 2010-08-18 台湾尖端先进生技医药股份有限公司 恩罗氟沙星的单株抗体及其检测套组
US20100247687A1 (en) * 2009-03-30 2010-09-30 Mary Arnold-Ronish Formulation for tattoo removal and method of using same
CN101810569B (zh) * 2010-05-22 2011-09-21 鼎正动物药业(天津)有限公司 一种恩诺沙星注射液及其制备方法
CN103479569A (zh) * 2013-01-14 2014-01-01 四川喜亚动物药业有限公司 兽用环丙沙星注射液及其制备方法
RU2574007C2 (ru) * 2013-10-16 2016-01-27 Олег Иванович Киселев Инъекционный раствор для лечения вирусных заболеваний, выбранных из гриппа h1n1, h3n2, h5n1, клещевого энцефалита и лихорадки западного нила
US9993421B2 (en) * 2015-11-20 2018-06-12 Dynamo, Llc Method for treating deleterious effects arising from tattoos
CN107095848A (zh) * 2017-07-01 2017-08-29 山东中牧兽药有限公司 一种恩诺沙星注射液及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
ES8304117A1 (es) * 1981-06-11 1983-02-16 Warner Lambert Co "un procedimiento para preparar sales de compuestos de naftiridina y quinoleina".
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure

Also Published As

Publication number Publication date
IL116726A0 (en) 1996-05-14
NO313537B1 (no) 2002-10-21
FI972966A (fi) 1997-07-11
FI972966A0 (fi) 1997-07-11
JO1883B1 (en) 1996-07-25
SK94697A3 (en) 1997-11-05
CN1125635C (zh) 2003-10-29
NZ298778A (en) 1999-05-28
TW416852B (en) 2001-01-01
ATE261731T1 (de) 2004-04-15
JP3835815B2 (ja) 2006-10-18
AR002265A1 (es) 1998-03-11
DK0806955T3 (da) 2004-07-12
ES2215183T3 (es) 2004-10-01
DE19500784A1 (de) 1996-07-18
ZA96244B (en) 1996-07-31
BR9510444A (pt) 1998-05-19
NO973223L (no) 1997-07-10
AU4434996A (en) 1996-07-31
CZ213097A3 (en) 1997-10-15
WO1996021453A1 (de) 1996-07-18
US5998418A (en) 1999-12-07
RU2147225C1 (ru) 2000-04-10
EP0806955A1 (de) 1997-11-19
CN1177300A (zh) 1998-03-25
PL321259A1 (en) 1997-11-24
CZ293934B6 (cs) 2004-08-18
JPH10511967A (ja) 1998-11-17
SK284348B6 (sk) 2005-02-04
EP0806955B1 (de) 2004-03-17
DE59510878D1 (de) 2004-04-22
CA2210076C (en) 2007-12-18
UA42819C2 (uk) 2001-11-15
AU695171B2 (en) 1998-08-06
HUT77942A (hu) 1998-12-28
MX9705266A (es) 1997-10-31
PL182095B1 (pl) 2001-11-30
IL116726A (en) 2000-07-16
HU226826B1 (en) 2009-11-30
CA2210076A1 (en) 1996-07-18
NO973223D0 (no) 1997-07-10
PT806955E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
FI119970B (fi) Enrofloksasiini-injektio- tai infuusioliuoksia
FI101596B (fi) Menetelmä valmistaa stabiili injisoitava florfenikolin farmaseuttinen seos
FI83286C (fi) Foerfarande foer framstaellning av mjoelksyrasaltloesningar av piperazinylkinolon- och piperazinylazakinolonkarboxylsyror.
KR900008441B1 (ko) 옥시캄 유도체를 함유하는 제약조성물의 제조방법
JPH0413325B2 (xx)
CZ281142B6 (cs) Roztoky léčiva se zvýšenou stabilitou a bez účinků poškozujících tkáň a způsob jejich přípravy
JPS605567B2 (ja) オキシテトラサイクリンの調合液
HUT67672A (en) Sparfloxacine solution and process for producing that
FI70793C (fi) Foerfarande foer framstaellning av en stabil 4'-(9-akridinylamino)metansulfon -m-anisidin(m-amsa)-komposition
HU226554B1 (en) Freeze-dried composition of bone morphogenetic protein human mp52
HU199289B (en) Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid
KR100446098B1 (ko) 엔로플록사신주사제또는주입액제
JP4475405B2 (ja) 医薬組成物
US5034397A (en) Stable, water soluble salt compositions of M-AMSA in 1-methyl-2-pyrrolidinone
KR20140130881A (ko) 보리코나졸을 함유하는 안정한 주사용 조성물
JPH0283314A (ja) 安定な脂溶性物質の水溶液
KR810002136B1 (ko) 아목시실린 나트륨 함유 주사용 약제조성물의 제조방법
KR960004019B1 (ko) 니모디핀의 가용화 방법
HU211477A9 (hu) Bisz-indol-alkaloid-sót tartalmazó injekciós oldat

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BAYER ANIMAL HEALTH GMBH

Free format text: BAYER ANIMAL HEALTH GMBH

FG Patent granted

Ref document number: 119970

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

MM Patent lapsed